| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 112 | 2023 | 1175 | 12.210 |
Why?
|
| Cognition | 72 | 2023 | 1025 | 9.580 |
Why?
|
| Alzheimer Disease | 80 | 2023 | 1406 | 9.310 |
Why?
|
| Health Literacy | 19 | 2023 | 87 | 8.380 |
Why?
|
| Cognitive Dysfunction | 52 | 2025 | 803 | 8.070 |
Why?
|
| Decision Making | 21 | 2023 | 179 | 7.160 |
Why?
|
| Cognition Disorders | 59 | 2019 | 724 | 6.700 |
Why?
|
| Aged, 80 and over | 194 | 2025 | 3857 | 6.590 |
Why?
|
| Aged | 230 | 2025 | 7638 | 5.990 |
Why?
|
| Brain | 63 | 2023 | 1241 | 5.970 |
Why?
|
| Independent Living | 19 | 2025 | 240 | 4.930 |
Why?
|
| Longitudinal Studies | 78 | 2025 | 1103 | 4.350 |
Why?
|
| Male | 228 | 2025 | 12636 | 4.330 |
Why?
|
| Female | 223 | 2025 | 13117 | 4.330 |
Why?
|
| Dementia | 30 | 2021 | 415 | 4.310 |
Why?
|
| Neuropsychological Tests | 81 | 2022 | 916 | 4.250 |
Why?
|
| Humans | 282 | 2025 | 23156 | 4.110 |
Why?
|
| Cohort Studies | 83 | 2023 | 1463 | 3.270 |
Why?
|
| Cerebral Amyloid Angiopathy | 7 | 2023 | 96 | 2.240 |
Why?
|
| Delivery of Health Care | 7 | 2023 | 122 | 2.210 |
Why?
|
| Neurodegenerative Diseases | 7 | 2021 | 98 | 2.110 |
Why?
|
| Activities of Daily Living | 27 | 2014 | 368 | 2.000 |
Why?
|
| Cognitive Aging | 5 | 2021 | 64 | 1.990 |
Why?
|
| TDP-43 Proteinopathies | 8 | 2021 | 87 | 1.880 |
Why?
|
| Delay Discounting | 4 | 2023 | 20 | 1.850 |
Why?
|
| DNA-Binding Proteins | 10 | 2019 | 231 | 1.810 |
Why?
|
| Memory, Episodic | 10 | 2022 | 81 | 1.790 |
Why?
|
| Financial Management | 5 | 2020 | 18 | 1.790 |
Why?
|
| Educational Status | 20 | 2023 | 223 | 1.720 |
Why?
|
| White Matter | 6 | 2020 | 113 | 1.710 |
Why?
|
| Hippocampus | 10 | 2022 | 196 | 1.630 |
Why?
|
| Memory | 23 | 2018 | 223 | 1.480 |
Why?
|
| Middle Aged | 90 | 2021 | 7964 | 1.480 |
Why?
|
| Neuropathology | 5 | 2022 | 63 | 1.450 |
Why?
|
| Magnetic Resonance Imaging | 18 | 2023 | 871 | 1.440 |
Why?
|
| Choice Behavior | 4 | 2019 | 40 | 1.430 |
Why?
|
| Residence Characteristics | 16 | 2021 | 179 | 1.410 |
Why?
|
| Disease Progression | 21 | 2021 | 543 | 1.340 |
Why?
|
| Economics | 4 | 2019 | 13 | 1.300 |
Why?
|
| Dementia, Vascular | 9 | 2018 | 36 | 1.300 |
Why?
|
| Age Factors | 42 | 2021 | 650 | 1.270 |
Why?
|
| Blood Glucose | 2 | 2022 | 104 | 1.260 |
Why?
|
| Income | 8 | 2023 | 67 | 1.260 |
Why?
|
| Risk Factors | 47 | 2022 | 2019 | 1.240 |
Why?
|
| Hospitalization | 5 | 2019 | 287 | 1.230 |
Why?
|
| Autopsy | 18 | 2021 | 260 | 1.200 |
Why?
|
| Mortality | 10 | 2021 | 76 | 1.200 |
Why?
|
| Motor Activity | 16 | 2015 | 274 | 1.170 |
Why?
|
| Amyloid beta-Peptides | 8 | 2023 | 210 | 1.160 |
Why?
|
| Lewy Bodies | 12 | 2021 | 151 | 1.150 |
Why?
|
| Literacy | 2 | 2019 | 14 | 1.130 |
Why?
|
| Prospective Studies | 22 | 2025 | 1511 | 1.090 |
Why?
|
| Neoplasms | 9 | 2009 | 218 | 1.060 |
Why?
|
| Quality of Life | 12 | 2015 | 564 | 1.060 |
Why?
|
| Fraud | 4 | 2022 | 17 | 1.060 |
Why?
|
| Financing, Personal | 5 | 2020 | 17 | 1.060 |
Why?
|
| Muscle Strength | 11 | 2012 | 99 | 1.010 |
Why?
|
| Perception | 3 | 2019 | 66 | 0.970 |
Why?
|
| Goals | 3 | 2010 | 35 | 0.940 |
Why?
|
| Geriatric Assessment | 12 | 2015 | 171 | 0.940 |
Why?
|
| Prostatic Hyperplasia | 8 | 2004 | 13 | 0.930 |
Why?
|
| Disability Evaluation | 9 | 2015 | 225 | 0.920 |
Why?
|
| Loneliness | 4 | 2020 | 45 | 0.910 |
Why?
|
| Incidence | 33 | 2019 | 631 | 0.910 |
Why?
|
| Nervous System Diseases | 5 | 2019 | 101 | 0.890 |
Why?
|
| Nerve Degeneration | 3 | 2014 | 34 | 0.890 |
Why?
|
| Neurofibrillary Tangles | 10 | 2019 | 121 | 0.890 |
Why?
|
| Chicago | 15 | 2025 | 847 | 0.870 |
Why?
|
| Proportional Hazards Models | 17 | 2019 | 279 | 0.860 |
Why?
|
| Crime Victims | 2 | 2022 | 23 | 0.850 |
Why?
|
| Sex Factors | 29 | 2019 | 399 | 0.850 |
Why?
|
| Apolipoprotein E4 | 8 | 2025 | 184 | 0.850 |
Why?
|
| Medicare | 3 | 2023 | 108 | 0.830 |
Why?
|
| Hypertension | 3 | 2022 | 169 | 0.830 |
Why?
|
| Government | 1 | 2023 | 2 | 0.810 |
Why?
|
| Awareness | 5 | 2019 | 40 | 0.800 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 775 | 0.780 |
Why?
|
| Life Style | 4 | 2021 | 167 | 0.770 |
Why?
|
| Blood Pressure | 4 | 2022 | 171 | 0.760 |
Why?
|
| Memory, Short-Term | 4 | 2019 | 81 | 0.760 |
Why?
|
| Arteriolosclerosis | 2 | 2023 | 61 | 0.760 |
Why?
|
| Follow-Up Studies | 25 | 2019 | 1430 | 0.750 |
Why?
|
| Brain Mapping | 4 | 2018 | 124 | 0.740 |
Why?
|
| Atherosclerosis | 1 | 2023 | 47 | 0.740 |
Why?
|
| Chronic Disease | 4 | 2017 | 377 | 0.740 |
Why?
|
| Information Literacy | 3 | 2019 | 6 | 0.730 |
Why?
|
| Metacognition | 1 | 2021 | 4 | 0.710 |
Why?
|
| Adult | 57 | 2022 | 6942 | 0.710 |
Why?
|
| Elder Abuse | 1 | 2022 | 34 | 0.700 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2021 | 7 | 0.700 |
Why?
|
| Age of Onset | 2 | 2021 | 74 | 0.700 |
Why?
|
| Reward | 2 | 2019 | 18 | 0.690 |
Why?
|
| Plaque, Amyloid | 7 | 2019 | 90 | 0.660 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 72 | 0.660 |
Why?
|
| Memory Disorders | 9 | 2019 | 115 | 0.650 |
Why?
|
| Limbic Encephalitis | 1 | 2020 | 10 | 0.650 |
Why?
|
| Depression | 9 | 2021 | 383 | 0.640 |
Why?
|
| Learning | 2 | 2018 | 59 | 0.640 |
Why?
|
| Stroke | 1 | 2023 | 243 | 0.620 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 11 | 0.610 |
Why?
|
| Risk | 11 | 2019 | 166 | 0.600 |
Why?
|
| Prodromal Symptoms | 1 | 2019 | 13 | 0.590 |
Why?
|
| Cerebral Infarction | 8 | 2015 | 113 | 0.580 |
Why?
|
| Mobility Limitation | 7 | 2019 | 78 | 0.570 |
Why?
|
| Agnosia | 2 | 2016 | 7 | 0.560 |
Why?
|
| United States | 17 | 2023 | 1796 | 0.560 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 148 | 0.550 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2018 | 41 | 0.540 |
Why?
|
| Disabled Persons | 6 | 2019 | 89 | 0.540 |
Why?
|
| Ambulatory Care | 1 | 2017 | 66 | 0.510 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 150 | 0.500 |
Why?
|
| Postmortem Changes | 1 | 2016 | 22 | 0.490 |
Why?
|
| Temporal Lobe | 5 | 2020 | 57 | 0.480 |
Why?
|
| Frail Elderly | 3 | 2014 | 37 | 0.480 |
Why?
|
| Intention | 3 | 2010 | 16 | 0.470 |
Why?
|
| Time Factors | 19 | 2020 | 1264 | 0.470 |
Why?
|
| Cognitive Reserve | 3 | 2021 | 24 | 0.460 |
Why?
|
| Regression Analysis | 16 | 2015 | 215 | 0.460 |
Why?
|
| Caregivers | 4 | 2006 | 192 | 0.460 |
Why?
|
| Surveys and Questionnaires | 14 | 2018 | 1036 | 0.440 |
Why?
|
| Risk-Taking | 2 | 2011 | 28 | 0.430 |
Why?
|
| Europe | 14 | 2009 | 51 | 0.430 |
Why?
|
| Frontal Lobe | 4 | 2018 | 57 | 0.420 |
Why?
|
| Sclerosis | 6 | 2020 | 54 | 0.420 |
Why?
|
| Cause of Death | 6 | 2009 | 56 | 0.410 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2021 | 176 | 0.400 |
Why?
|
| Genome-Wide Association Study | 5 | 2021 | 160 | 0.400 |
Why?
|
| Mood Disorders | 2 | 2003 | 23 | 0.400 |
Why?
|
| Urinary Retention | 3 | 2004 | 12 | 0.390 |
Why?
|
| Social Class | 3 | 2022 | 57 | 0.380 |
Why?
|
| Cerebrovascular Disorders | 4 | 2021 | 104 | 0.380 |
Why?
|
| Health Status | 7 | 2019 | 204 | 0.380 |
Why?
|
| Personality | 3 | 2021 | 42 | 0.370 |
Why?
|
| Adolescent | 20 | 2018 | 1883 | 0.370 |
Why?
|
| Child, Preschool | 14 | 2013 | 569 | 0.370 |
Why?
|
| Child | 17 | 2013 | 1160 | 0.370 |
Why?
|
| Comorbidity | 8 | 2018 | 429 | 0.360 |
Why?
|
| Risk Assessment | 7 | 2015 | 550 | 0.360 |
Why?
|
| Finasteride | 2 | 2004 | 3 | 0.350 |
Why?
|
| Statistics as Topic | 6 | 2017 | 85 | 0.340 |
Why?
|
| Illinois | 5 | 2020 | 224 | 0.340 |
Why?
|
| Mental Health | 4 | 2019 | 96 | 0.340 |
Why?
|
| Enzyme Inhibitors | 2 | 2004 | 104 | 0.330 |
Why?
|
| Urologic Diseases | 3 | 2003 | 5 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 277 | 0.330 |
Why?
|
| Environmental Health | 1 | 2010 | 7 | 0.330 |
Why?
|
| Severity of Illness Index | 13 | 2015 | 804 | 0.320 |
Why?
|
| Phobic Disorders | 1 | 2010 | 65 | 0.320 |
Why?
|
| Models, Statistical | 5 | 2012 | 116 | 0.320 |
Why?
|
| Brain Infarction | 4 | 2018 | 63 | 0.320 |
Why?
|
| Psychomotor Performance | 6 | 2019 | 162 | 0.320 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 269 | 0.320 |
Why?
|
| Death | 2 | 2020 | 40 | 0.310 |
Why?
|
| Data Collection | 1 | 2010 | 83 | 0.310 |
Why?
|
| Infant | 12 | 2009 | 483 | 0.310 |
Why?
|
| Neurologic Examination | 4 | 2020 | 82 | 0.300 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2020 | 48 | 0.300 |
Why?
|
| Linear Models | 7 | 2018 | 202 | 0.300 |
Why?
|
| Multifactorial Inheritance | 3 | 2018 | 12 | 0.290 |
Why?
|
| Brain Diseases | 3 | 2020 | 56 | 0.290 |
Why?
|
| Lewy Body Disease | 5 | 2018 | 74 | 0.290 |
Why?
|
| Parkinsonian Disorders | 2 | 2014 | 170 | 0.290 |
Why?
|
| Frontotemporal Lobar Degeneration | 2 | 2019 | 22 | 0.280 |
Why?
|
| Prognosis | 6 | 2017 | 730 | 0.280 |
Why?
|
| Self Report | 5 | 2022 | 202 | 0.280 |
Why?
|
| Urination Disorders | 3 | 2003 | 7 | 0.280 |
Why?
|
| Brain Neoplasms | 3 | 1994 | 71 | 0.270 |
Why?
|
| Executive Function | 2 | 2021 | 94 | 0.270 |
Why?
|
| Isometric Contraction | 1 | 2007 | 8 | 0.270 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2004 | 3 | 0.260 |
Why?
|
| Lower Extremity | 1 | 2007 | 33 | 0.260 |
Why?
|
| Adaptation, Psychological | 2 | 2022 | 168 | 0.260 |
Why?
|
| Infant, Newborn | 10 | 2009 | 537 | 0.260 |
Why?
|
| Trust | 2 | 2019 | 9 | 0.260 |
Why?
|
| Gait | 2 | 2007 | 384 | 0.250 |
Why?
|
| Postural Balance | 1 | 2007 | 105 | 0.240 |
Why?
|
| Biomarkers | 4 | 2025 | 481 | 0.240 |
Why?
|
| Sex Characteristics | 3 | 2022 | 91 | 0.240 |
Why?
|
| Stress, Psychological | 4 | 2014 | 215 | 0.240 |
Why?
|
| Behavior Therapy | 1 | 2006 | 85 | 0.240 |
Why?
|
| Primary Prevention | 2 | 2019 | 22 | 0.240 |
Why?
|
| Atrophy | 3 | 2021 | 65 | 0.230 |
Why?
|
| Cost of Illness | 1 | 2005 | 44 | 0.230 |
Why?
|
| Self Efficacy | 1 | 2005 | 52 | 0.230 |
Why?
|
| Cerebral Cortex | 3 | 2019 | 128 | 0.230 |
Why?
|
| Mouth Neoplasms | 6 | 1997 | 20 | 0.230 |
Why?
|
| Reference Values | 3 | 2020 | 168 | 0.230 |
Why?
|
| Sex Distribution | 6 | 2012 | 66 | 0.220 |
Why?
|
| Interpersonal Relations | 3 | 2014 | 91 | 0.220 |
Why?
|
| Age Distribution | 6 | 2007 | 69 | 0.220 |
Why?
|
| Demography | 3 | 2018 | 60 | 0.220 |
Why?
|
| Gray Matter | 2 | 2016 | 43 | 0.220 |
Why?
|
| Personal Satisfaction | 2 | 2016 | 39 | 0.220 |
Why?
|
| Neural Pathways | 3 | 2014 | 54 | 0.220 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2004 | 4 | 0.210 |
Why?
|
| Apolipoproteins E | 3 | 2013 | 160 | 0.210 |
Why?
|
| Anxiety | 3 | 2019 | 143 | 0.210 |
Why?
|
| Longevity | 3 | 2013 | 19 | 0.210 |
Why?
|
| Data Interpretation, Statistical | 2 | 2022 | 63 | 0.210 |
Why?
|
| Problem Solving | 1 | 2004 | 38 | 0.210 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2003 | 13 | 0.200 |
Why?
|
| Government Agencies | 1 | 2023 | 2 | 0.200 |
Why?
|
| Adenocarcinoma | 5 | 2001 | 135 | 0.200 |
Why?
|
| Anxiety Disorders | 2 | 2016 | 164 | 0.200 |
Why?
|
| Individuality | 2 | 2021 | 15 | 0.200 |
Why?
|
| Motivation | 1 | 2003 | 83 | 0.200 |
Why?
|
| Prefrontal Cortex | 2 | 2014 | 104 | 0.190 |
Why?
|
| Anisotropy | 2 | 2020 | 36 | 0.190 |
Why?
|
| Models, Theoretical | 1 | 2003 | 76 | 0.190 |
Why?
|
| Erectile Dysfunction | 1 | 2003 | 53 | 0.190 |
Why?
|
| Infarction | 1 | 2023 | 21 | 0.190 |
Why?
|
| Mental Recall | 2 | 2020 | 49 | 0.190 |
Why?
|
| Survival Rate | 3 | 2012 | 320 | 0.190 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2019 | 46 | 0.190 |
Why?
|
| Reaction Time | 2 | 2020 | 81 | 0.190 |
Why?
|
| Motor Skills | 2 | 2013 | 38 | 0.190 |
Why?
|
| Predictive Value of Tests | 7 | 2008 | 437 | 0.190 |
Why?
|
| Laryngeal Neoplasms | 2 | 1996 | 28 | 0.190 |
Why?
|
| Smoking | 8 | 2001 | 163 | 0.180 |
Why?
|
| Psychometrics | 3 | 2014 | 184 | 0.170 |
Why?
|
| Neurons | 2 | 2013 | 273 | 0.170 |
Why?
|
| Alcohol Drinking | 5 | 1998 | 65 | 0.170 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 31 | 0.170 |
Why?
|
| tau Proteins | 5 | 2025 | 153 | 0.170 |
Why?
|
| Memory and Learning Tests | 1 | 2020 | 5 | 0.170 |
Why?
|
| Mental Disorders | 2 | 2018 | 134 | 0.170 |
Why?
|
| Serial Learning | 1 | 2020 | 6 | 0.170 |
Why?
|
| Healthy Aging | 1 | 2020 | 13 | 0.160 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 42 | 0.160 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2002 | 120 | 0.160 |
Why?
|
| Musculoskeletal Diseases | 2 | 2010 | 30 | 0.160 |
Why?
|
| Frailty | 1 | 2020 | 22 | 0.160 |
Why?
|
| Depressive Disorder, Major | 2 | 2016 | 88 | 0.160 |
Why?
|
| Space Perception | 1 | 2019 | 19 | 0.160 |
Why?
|
| Self Concept | 1 | 2020 | 38 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 1998 | 30 | 0.150 |
Why?
|
| Testicular Neoplasms | 2 | 1998 | 20 | 0.150 |
Why?
|
| Korea | 3 | 2003 | 10 | 0.150 |
Why?
|
| Case-Control Studies | 10 | 2002 | 485 | 0.150 |
Why?
|
| Neuronal Plasticity | 1 | 2019 | 38 | 0.150 |
Why?
|
| Breast Neoplasms | 5 | 2002 | 375 | 0.150 |
Why?
|
| Kidney | 2 | 2010 | 142 | 0.150 |
Why?
|
| Emergencies | 1 | 2019 | 28 | 0.140 |
Why?
|
| Renal Dialysis | 1 | 1999 | 82 | 0.140 |
Why?
|
| Computer Graphics | 1 | 1998 | 4 | 0.140 |
Why?
|
| Lung | 2 | 2009 | 138 | 0.140 |
Why?
|
| Mental Status Schedule | 3 | 2007 | 72 | 0.140 |
Why?
|
| France | 5 | 2003 | 13 | 0.140 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2018 | 17 | 0.140 |
Why?
|
| Logistic Models | 7 | 2016 | 356 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 1 | 1999 | 121 | 0.140 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 21 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 226 | 0.140 |
Why?
|
| Pain | 2 | 2010 | 332 | 0.130 |
Why?
|
| Muscle Weakness | 2 | 2008 | 27 | 0.130 |
Why?
|
| Lung Neoplasms | 5 | 2003 | 539 | 0.130 |
Why?
|
| Registries | 5 | 2003 | 174 | 0.130 |
Why?
|
| Social Behavior | 2 | 2011 | 54 | 0.130 |
Why?
|
| Gallbladder Neoplasms | 2 | 1999 | 6 | 0.130 |
Why?
|
| Connecticut | 8 | 2002 | 9 | 0.130 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1997 | 6 | 0.130 |
Why?
|
| Gene Expression | 1 | 2017 | 180 | 0.130 |
Why?
|
| Brain Stem | 2 | 2016 | 16 | 0.130 |
Why?
|
| Deafness | 1 | 1997 | 12 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2017 | 283 | 0.130 |
Why?
|
| Cochlear Implantation | 1 | 1997 | 18 | 0.130 |
Why?
|
| Scotland | 7 | 2007 | 7 | 0.130 |
Why?
|
| Personality Development | 1 | 2016 | 5 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2017 | 129 | 0.120 |
Why?
|
| Locus Coeruleus | 2 | 2013 | 16 | 0.120 |
Why?
|
| Germinoma | 1 | 1996 | 1 | 0.120 |
Why?
|
| Neurotic Disorders | 2 | 2018 | 15 | 0.120 |
Why?
|
| Affect | 1 | 2016 | 57 | 0.120 |
Why?
|
| Thyroid Neoplasms | 1 | 1996 | 41 | 0.120 |
Why?
|
| Fetus | 1 | 2016 | 33 | 0.120 |
Why?
|
| Intelligence | 1 | 2016 | 14 | 0.120 |
Why?
|
| Psychological Tests | 2 | 2015 | 43 | 0.120 |
Why?
|
| Brain Chemistry | 1 | 2016 | 33 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2016 | 273 | 0.120 |
Why?
|
| Comprehension | 1 | 2016 | 25 | 0.120 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2016 | 36 | 0.120 |
Why?
|
| Vascular Diseases | 2 | 2013 | 34 | 0.120 |
Why?
|
| Organ Size | 1 | 2015 | 86 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 37 | 0.110 |
Why?
|
| Muscle, Skeletal | 2 | 2008 | 341 | 0.110 |
Why?
|
| Patient Satisfaction | 3 | 2003 | 257 | 0.110 |
Why?
|
| Poverty | 1 | 2015 | 85 | 0.110 |
Why?
|
| Gyrus Cinguli | 1 | 2014 | 13 | 0.110 |
Why?
|
| Music | 1 | 2014 | 20 | 0.110 |
Why?
|
| Harm Reduction | 1 | 2014 | 5 | 0.110 |
Why?
|
| Language | 2 | 2014 | 57 | 0.110 |
Why?
|
| Multilingualism | 1 | 2014 | 19 | 0.110 |
Why?
|
| Anticarcinogenic Agents | 2 | 2000 | 18 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1994 | 7 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2016 | 139 | 0.100 |
Why?
|
| Mesencephalon | 1 | 2013 | 21 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 192 | 0.100 |
Why?
|
| Medicare Part D | 1 | 2013 | 6 | 0.100 |
Why?
|
| Cerebellum | 1 | 2013 | 34 | 0.100 |
Why?
|
| Attitude to Health | 3 | 2003 | 91 | 0.100 |
Why?
|
| Retirement | 2 | 2011 | 9 | 0.100 |
Why?
|
| Causality | 3 | 2012 | 44 | 0.100 |
Why?
|
| Psychomotor Disorders | 1 | 2013 | 9 | 0.100 |
Why?
|
| Neuroticism | 3 | 2021 | 23 | 0.100 |
Why?
|
| Prevalence | 4 | 2012 | 380 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2004 | 312 | 0.100 |
Why?
|
| Retinoids | 1 | 1992 | 5 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 13 | 0.100 |
Why?
|
| Leukoplakia, Oral | 1 | 1992 | 3 | 0.100 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2012 | 20 | 0.090 |
Why?
|
| Odds Ratio | 6 | 2007 | 227 | 0.090 |
Why?
|
| Colonic Neoplasms | 2 | 2000 | 56 | 0.090 |
Why?
|
| Child Abuse | 1 | 2012 | 29 | 0.090 |
Why?
|
| Terminally Ill | 1 | 2012 | 4 | 0.090 |
Why?
|
| Movement Disorders | 1 | 2012 | 57 | 0.090 |
Why?
|
| Models, Psychological | 1 | 2012 | 61 | 0.090 |
Why?
|
| Emotions | 1 | 2012 | 69 | 0.090 |
Why?
|
| Health Surveys | 2 | 2007 | 78 | 0.090 |
Why?
|
| Urban Population | 2 | 2010 | 131 | 0.090 |
Why?
|
| Respiratory Muscles | 2 | 2008 | 13 | 0.090 |
Why?
|
| Alleles | 4 | 2015 | 172 | 0.090 |
Why?
|
| England | 2 | 2003 | 14 | 0.090 |
Why?
|
| Diet | 5 | 2000 | 181 | 0.090 |
Why?
|
| Acute Disease | 3 | 2004 | 163 | 0.090 |
Why?
|
| Social Environment | 1 | 2011 | 71 | 0.090 |
Why?
|
| Odorants | 2 | 2009 | 15 | 0.090 |
Why?
|
| Social Participation | 1 | 2011 | 11 | 0.080 |
Why?
|
| Leg | 2 | 2008 | 40 | 0.080 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 14 | 0.080 |
Why?
|
| Body Mass Index | 5 | 2012 | 381 | 0.080 |
Why?
|
| Knowledge | 1 | 2010 | 12 | 0.080 |
Why?
|
| Potassium | 2 | 2010 | 59 | 0.080 |
Why?
|
| Beer | 1 | 1990 | 2 | 0.080 |
Why?
|
| Alcoholic Beverages | 1 | 1990 | 3 | 0.080 |
Why?
|
| Italy | 5 | 1998 | 15 | 0.080 |
Why?
|
| Physical Fitness | 2 | 2008 | 48 | 0.080 |
Why?
|
| Neuroimaging | 2 | 2022 | 105 | 0.080 |
Why?
|
| Housing for the Elderly | 1 | 2010 | 6 | 0.080 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2009 | 13 | 0.080 |
Why?
|
| United Kingdom | 3 | 2016 | 40 | 0.080 |
Why?
|
| Social Adjustment | 1 | 2009 | 21 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 1990 | 88 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2012 | 77 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2009 | 36 | 0.070 |
Why?
|
| Olfaction Disorders | 1 | 2009 | 38 | 0.070 |
Why?
|
| Community Health Services | 1 | 2009 | 27 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 444 | 0.070 |
Why?
|
| Exercise | 4 | 2012 | 404 | 0.070 |
Why?
|
| Depressive Disorder | 3 | 2007 | 163 | 0.070 |
Why?
|
| Forecasting | 2 | 2009 | 79 | 0.070 |
Why?
|
| Epidemiologic Studies | 2 | 2005 | 18 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 594 | 0.070 |
Why?
|
| Hand Strength | 1 | 2007 | 49 | 0.070 |
Why?
|
| Epidemiologic Methods | 3 | 2015 | 15 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 27 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2001 | 162 | 0.070 |
Why?
|
| Epidemiology | 1 | 2007 | 5 | 0.060 |
Why?
|
| Observation | 1 | 2007 | 5 | 0.060 |
Why?
|
| Massachusetts | 1 | 2006 | 16 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 96 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 125 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2019 | 2989 | 0.060 |
Why?
|
| Netherlands | 2 | 2003 | 25 | 0.060 |
Why?
|
| Exercise Therapy | 1 | 2007 | 84 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2018 | 31 | 0.060 |
Why?
|
| Cerebral Arteries | 1 | 2005 | 21 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2003 | 40 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2006 | 2942 | 0.060 |
Why?
|
| Interview, Psychological | 1 | 2005 | 39 | 0.060 |
Why?
|
| Home Nursing | 1 | 2005 | 33 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 1985 | 15 | 0.060 |
Why?
|
| Social Support | 2 | 2020 | 180 | 0.060 |
Why?
|
| Sertraline | 2 | 2002 | 24 | 0.060 |
Why?
|
| Models, Biological | 1 | 1987 | 302 | 0.060 |
Why?
|
| Neurofilament Proteins | 1 | 2025 | 17 | 0.060 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2025 | 39 | 0.060 |
Why?
|
| Young Adult | 3 | 2018 | 1654 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 295 | 0.050 |
Why?
|
| New South Wales | 2 | 1994 | 3 | 0.050 |
Why?
|
| Heterozygote | 2 | 2015 | 90 | 0.050 |
Why?
|
| Libido | 1 | 2003 | 6 | 0.050 |
Why?
|
| Ejaculation | 1 | 2003 | 8 | 0.050 |
Why?
|
| Australia | 3 | 1999 | 20 | 0.050 |
Why?
|
| Vital Statistics | 1 | 2003 | 1 | 0.050 |
Why?
|
| Azasteroids | 1 | 2003 | 2 | 0.050 |
Why?
|
| Genotype | 2 | 2015 | 265 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2003 | 58 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 2 | 2001 | 54 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2003 | 226 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2003 | 103 | 0.050 |
Why?
|
| Observer Variation | 1 | 2003 | 83 | 0.050 |
Why?
|
| Hair Dyes | 1 | 2002 | 1 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2003 | 173 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 5 | 0.050 |
Why?
|
| Health Behavior | 2 | 2014 | 140 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2021 | 37 | 0.040 |
Why?
|
| Brazil | 1 | 2021 | 35 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2002 | 89 | 0.040 |
Why?
|
| Japan | 5 | 2001 | 6 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2021 | 94 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2021 | 140 | 0.040 |
Why?
|
| Spouses | 1 | 2000 | 31 | 0.040 |
Why?
|
| Switzerland | 2 | 1990 | 8 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 59 | 0.040 |
Why?
|
| Nails | 1 | 2000 | 1 | 0.040 |
Why?
|
| Selenium | 1 | 2000 | 6 | 0.040 |
Why?
|
| Feeding Behavior | 2 | 1998 | 79 | 0.040 |
Why?
|
| New Zealand | 1 | 1999 | 10 | 0.040 |
Why?
|
| Women's Health | 1 | 2001 | 174 | 0.040 |
Why?
|
| Frontotemporal Dementia | 1 | 2019 | 11 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2000 | 110 | 0.040 |
Why?
|
| Proteomics | 1 | 2019 | 58 | 0.040 |
Why?
|
| Algorithms | 1 | 2021 | 304 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2000 | 92 | 0.040 |
Why?
|
| Wales | 1 | 1998 | 5 | 0.040 |
Why?
|
| Spain | 1 | 1998 | 8 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 338 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 1998 | 22 | 0.040 |
Why?
|
| Religious Personnel | 1 | 2018 | 9 | 0.030 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 8 | 0.030 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 12 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 25 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 35 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1997 | 25 | 0.030 |
Why?
|
| Gingival Neoplasms | 1 | 1997 | 1 | 0.030 |
Why?
|
| Sampling Studies | 3 | 2002 | 23 | 0.030 |
Why?
|
| Czechoslovakia | 2 | 2001 | 2 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 1996 | 15 | 0.030 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1996 | 8 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1996 | 16 | 0.030 |
Why?
|
| Time | 1 | 1996 | 14 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 23 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 1996 | 16 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1996 | 21 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1996 | 10 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1996 | 21 | 0.030 |
Why?
|
| Radiotherapy | 1 | 1996 | 30 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 3 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 12 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 13 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 17 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 121 | 0.030 |
Why?
|
| Seminoma | 1 | 1996 | 3 | 0.030 |
Why?
|
| Vitamin A | 2 | 1993 | 7 | 0.030 |
Why?
|
| Speech Perception | 1 | 1997 | 47 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2016 | 46 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 32 | 0.030 |
Why?
|
| SEER Program | 1 | 1996 | 34 | 0.030 |
Why?
|
| Carotenoids | 2 | 1993 | 15 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1997 | 244 | 0.030 |
Why?
|
| Family Practice | 1 | 1995 | 13 | 0.030 |
Why?
|
| Urology | 1 | 1995 | 15 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 99 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 55 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 58 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 88 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 30 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 260 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 36 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 33 | 0.030 |
Why?
|
| Canada | 2 | 1994 | 42 | 0.030 |
Why?
|
| Germany | 1 | 1994 | 6 | 0.030 |
Why?
|
| Carcinoma | 1 | 1994 | 67 | 0.030 |
Why?
|
| Raphe Nuclei | 1 | 2013 | 5 | 0.030 |
Why?
|
| Ventral Tegmental Area | 1 | 2013 | 7 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 59 | 0.030 |
Why?
|
| Lip Neoplasms | 1 | 1993 | 2 | 0.030 |
Why?
|
| World Health Organization | 3 | 2003 | 8 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 72 | 0.030 |
Why?
|
| Fathers | 1 | 1994 | 21 | 0.030 |
Why?
|
| Prostate | 1 | 1994 | 30 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 29 | 0.030 |
Why?
|
| Religion | 1 | 2013 | 38 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2013 | 6 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 1993 | 32 | 0.020 |
Why?
|
| Developing Countries | 1 | 1993 | 13 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2013 | 102 | 0.020 |
Why?
|
| Pregnancy | 1 | 1994 | 324 | 0.020 |
Why?
|
| Isotretinoin | 1 | 1992 | 8 | 0.020 |
Why?
|
| Neocortex | 1 | 2012 | 23 | 0.020 |
Why?
|
| Poland | 1 | 1992 | 2 | 0.020 |
Why?
|
| Coffee | 1 | 1992 | 3 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1992 | 32 | 0.020 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1992 | 1 | 0.020 |
Why?
|
| Energy Intake | 1 | 1992 | 77 | 0.020 |
Why?
|
| Actigraphy | 1 | 2012 | 81 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 1992 | 50 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2012 | 42 | 0.020 |
Why?
|
| Games, Experimental | 1 | 2011 | 6 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 72 | 0.020 |
Why?
|
| Nerve Net | 1 | 2011 | 34 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 56 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 1992 | 66 | 0.020 |
Why?
|
| Parents | 1 | 2012 | 107 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 162 | 0.020 |
Why?
|
| Visual Perception | 1 | 2011 | 21 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 52 | 0.020 |
Why?
|
| Animals | 1 | 1998 | 3270 | 0.020 |
Why?
|
| Bulgaria | 1 | 1990 | 1 | 0.020 |
Why?
|
| Germany, West | 1 | 1990 | 1 | 0.020 |
Why?
|
| Yugoslavia | 1 | 1990 | 2 | 0.020 |
Why?
|
| Denmark | 1 | 1990 | 9 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 106 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1992 | 118 | 0.020 |
Why?
|
| Wine | 1 | 1990 | 6 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 25 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1989 | 19 | 0.020 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 1989 | 1 | 0.020 |
Why?
|
| Microcirculation | 1 | 2009 | 26 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 35 | 0.020 |
Why?
|
| Extremities | 1 | 2008 | 24 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2009 | 67 | 0.020 |
Why?
|
| Catholicism | 1 | 2007 | 13 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 22 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2007 | 19 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2007 | 44 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2007 | 30 | 0.020 |
Why?
|
| Clergy | 1 | 2007 | 72 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2007 | 129 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 288 | 0.020 |
Why?
|
| Porphyrias | 1 | 1985 | 1 | 0.010 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1985 | 24 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 1985 | 26 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1985 | 37 | 0.010 |
Why?
|
| Dietary Fiber | 1 | 1985 | 25 | 0.010 |
Why?
|
| Cohort Effect | 2 | 1994 | 2 | 0.010 |
Why?
|
| Dutasteride | 1 | 2003 | 2 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2003 | 88 | 0.010 |
Why?
|
| Death Certificates | 1 | 2003 | 1 | 0.010 |
Why?
|
| Citalopram | 1 | 2002 | 8 | 0.010 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2002 | 28 | 0.010 |
Why?
|
| Color | 1 | 2002 | 7 | 0.010 |
Why?
|
| Outpatients | 1 | 2002 | 56 | 0.010 |
Why?
|
| Slovakia | 1 | 2001 | 1 | 0.010 |
Why?
|
| Bendroflumethiazide | 1 | 1980 | 1 | 0.010 |
Why?
|
| Metolazone | 1 | 1980 | 1 | 0.010 |
Why?
|
| Diuretics | 1 | 1980 | 2 | 0.010 |
Why?
|
| Hawaii | 1 | 2000 | 2 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2000 | 105 | 0.010 |
Why?
|
| Neutron Activation Analysis | 1 | 2000 | 1 | 0.010 |
Why?
|
| Toes | 1 | 2000 | 3 | 0.010 |
Why?
|
| Cholelithiasis | 1 | 1999 | 6 | 0.010 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1999 | 20 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 1999 | 37 | 0.010 |
Why?
|
| beta Carotene | 1 | 1998 | 12 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2000 | 200 | 0.010 |
Why?
|
| Vitamin E | 1 | 1998 | 38 | 0.010 |
Why?
|
| Postmenopause | 1 | 1998 | 57 | 0.010 |
Why?
|
| Antioxidants | 1 | 1998 | 56 | 0.010 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 1994 | 2 | 0.010 |
Why?
|
| North America | 1 | 1994 | 32 | 0.010 |
Why?
|
| Public Health | 1 | 1994 | 47 | 0.010 |
Why?
|
| Cardia | 1 | 1993 | 3 | 0.010 |
Why?
|
| Helicobacter Infections | 1 | 1993 | 2 | 0.010 |
Why?
|
| Hernia, Hiatal | 1 | 1993 | 13 | 0.010 |
Why?
|
| Trace Elements | 1 | 1993 | 2 | 0.010 |
Why?
|
| Edible Grain | 1 | 1993 | 4 | 0.010 |
Why?
|
| Phosphorus | 1 | 1993 | 7 | 0.010 |
Why?
|
| Seafood | 1 | 1993 | 9 | 0.010 |
Why?
|
| Iron | 1 | 1993 | 14 | 0.010 |
Why?
|
| Vitamins | 1 | 1993 | 15 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 1993 | 11 | 0.010 |
Why?
|
| Fruit | 1 | 1993 | 24 | 0.010 |
Why?
|
| Vegetables | 1 | 1993 | 23 | 0.010 |
Why?
|
| Diet Surveys | 1 | 1993 | 24 | 0.010 |
Why?
|
| China | 1 | 1993 | 45 | 0.010 |
Why?
|
| Tongue Neoplasms | 1 | 1992 | 18 | 0.010 |
Why?
|
| Pleural Neoplasms | 1 | 1992 | 11 | 0.010 |
Why?
|
| Calcium | 1 | 1993 | 370 | 0.000 |
Why?
|
| Valsalva Maneuver | 1 | 1985 | 3 | 0.000 |
Why?
|
| Parasympathetic Nervous System | 1 | 1985 | 2 | 0.000 |
Why?
|
| Sympathetic Nervous System | 1 | 1985 | 13 | 0.000 |
Why?
|
| Respiration | 1 | 1985 | 27 | 0.000 |
Why?
|
| Posture | 1 | 1985 | 56 | 0.000 |
Why?
|
| Muscle Contraction | 1 | 1985 | 68 | 0.000 |
Why?
|
| Heart Rate | 1 | 1985 | 104 | 0.000 |
Why?
|